SCHEMBL3264156

SCHEMBL3264156

CCCc1ccc([Si](C)(C)C)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPL P06858 2/20 0.46
LIPG Q9Y5X9 2/20 0.46
CA2 P00918 1/20 0.43
MGLL Q99685 1/20 0.41
PLK1 P53350 1/20 0.41
NISCH Q9Y2I1 1/20 0.40
HTR1D P28221 1/20 0.40
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
THRB P10828 2/20 0.39
NPC1 O15118 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39
GFER P55789 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
DGAT1 O75907 1/20 0.36
POLB P06746 2/20 0.36
CTDSP1 Q9GZU7 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6510336 0.87 ESR1 (0.41) GFERGAA
SCHEMBL10356878 0.86 CA2 (0.50) LPLLIPGCA2PLK1NISCH
SCHEMBL5148656 0.82 HSD17B10 (0.59) LPLLIPGMGLLTHRBMAPT
SCHEMBL12707691 0.82 NISCH (0.37) LPLLIPGNISCHCNR1CNR2
SCHEMBL8377567 0.81 LPL (0.43) LPLLIPGCA2MGLLPLK1
SCHEMBL142480 0.81 LPL (0.62) LPLLIPGCA2MGLLPLK1
SCHEMBL8306401 0.79 TP53 (0.46) LPLLIPGCA2PLK1L3MBTL1
SCHEMBL19600562 0.78 TAAR1 (0.56) L3MBTL1KDM4EALDH1A1
SCHEMBL1395217 0.78 LPL (0.45) LPLLIPGCA2MGLLPLK1
SCHEMBL1686499 0.78 LPL (0.50) LPLLIPGCA2MGLLPLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303495-B1 SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY KRENITSKY PHARMACEUTICALS INC (US) 2010-05-26 EP disclosed
US-7205297-B2 Substituted 5-alkynyl pyrimidines having neurotrophic activity KRENITSKY PHARMACEUTICALS, INC. (US) 2007-04-17 US disclosed
US-20040087789-A1 Substituted 5-alkynyl pyrimidines having neurotrophic activity MIDCAP FUNDING III, LLC 2004-05-06 US disclosed
EP-1303495-A1 SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY Krenitsky Pharmaceuticals, Inc. (US) 2003-04-23 EP disclosed
WO-2002008205-A1 SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY KRENITSKY PHARMACEUTICALS, INC. (US) 2002-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087789-A1 Substituted 5-alkynyl pyrimidines having neurotrophic activity BDNF, NTRK2, GAP43 LPL 2543/4885LIPG 2554/4885CA2 4627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.